A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- John E. Janik, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Alabama Birmingham (uab)
Birmingham, Alabama, United States
- Scottsdale Healthcare Hospitals Dba Honorhealth
Scottsdale, Arizona, United States
- the Angeles Clinic and Research Institute
Los Angeles, California, United States
- Mount Sinai Medical Center of Florida, Inc.
Miami, Florida, United States
- University of Michigan
Ann Arbor, Michigan, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- John Theurer Cancer Center at Hackensack Umc
Hackensack, New Jersey, United States
- Rutgers, the State University
New Brunswick, New Jersey, United States
- New York University Clinical Cancer Center
New York, New York, United States
- University of Rochester Medical Center
Rochester, New York, United States
- Carolina Biooncology Institute
Huntersville, North Carolina, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute, Llc (scri)
Nashville, Tennessee, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Oct 2017
- Primary completion
- 17 Sept 2019
- Completion
- 17 Sept 2019
- Last update posted
- 27 Sept 2022
- Registered enrollment
- 52
- Registry id
- NCT03241173
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.